1 / 24

ABC, Bangkok, Thailand, March 19, 2007

Bioethics Concerns in Regulating L arge DNA Collections: The Israeli Experience David Gurwitz National Laboratory for the Genetics of Israeli Populations Sackler Faculty of Medicine, Tel-Aviv University gurwitz@post.tau.ac.il. ABC, Bangkok, Thailand, March 19, 2007. http://nlgip.tau.ac.il.

michael-stokes
Télécharger la présentation

ABC, Bangkok, Thailand, March 19, 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bioethics Concerns in Regulating Large DNA Collections:The Israeli ExperienceDavid GurwitzNational Laboratory for the Genetics of Israeli Populations Sackler Faculty of Medicine, Tel-Aviv Universitygurwitz@post.tau.ac.il ABC, Bangkok, Thailand, March 19, 2007

  2. http://nlgip.tau.ac.il

  3. Israelis Are Ethnically Diverse Jews immigrated to Israel from Asian, African and European countries, from communities that were genetically isolated for 1000 – 2000 yearsIsraeli Arabs include groups with minimal admixture:Palestinians, Bedouine, Druze This ethnic diversity is important in clinicla genetics and pharmacogenetics research

  4. Jewish immigration to Israel: 1948 - 2005(thousands of immigrants) 854 (mostly recent) 26 18 171 2 24 38 30 273 8 4 10 43 61 2 10 76 345 130 24 36 37 28 52 59

  5. The National Laboratory for the Genetics of Israeli Populations • The repository includes about 2000 cell lines and matching DNA samples, representing the ethnic diversity of the populations of Israel • Blood samples for preparation of cell lines are obtained from adult individuals (>18 y) with informed consent • Supervised by the TAU IRB

  6. http://nlgip.tau.ac.il

  7. Cell Lines in the NLGIP Collection Ashkenazi Jews Arab Arabs Arabs Sephardic Ethiopian Jews North-African Jews Oriental Jews

  8. Major Public Collections of Human Cell Lines and DNA samples Repository Human Lines Disease Ethnicity • Coriell: ~8,000 genetic few • ATCC: ~1,500 cancer few • ECACC: ~25,000 genetic few • Genethon: ~43,000 genetic few • NLGIP: ~2,000 healthy all

  9. Coding the samples • DNA samples are coded by four-digit codes • The only information supplied : ethnicity and gender • Example for information accompanying a DNA shipment: Unrelated Ashkenazi donors: Males 1102 1106 1113 1116 1154 1162 1254 1267 1363 1369 Females 1121 1124 1128 1129 1131 1133 1163 1265 1282 1283

  10. From the NLGIP DNA Request Form: I, the undersigned, state that: - The requested cell lines/DNA samples will be used in my laboratory only for research. - The cell lines/DNA samples will not be further distributed to other laboratories or any scientists.

  11. DNA Samples distributed by NLGIP:By Ethnic Groups Arabs 15% Ashkenazi Jews 44% Ethiopian 4% Oriental 14% North-African Jews 16% Sephardic Jews 7%

  12. DNA Samples distributed by NLGIP:By Countries Italy 3% Canada 5% Israel 27% Others 1% UK 7% Japan 14% USA 43%

  13. DNA Samples distributed by NLGIP:By Type of Institute Other Research Centers 6% National Research Institutes 28% Universities 66%

  14. Acetaminophen can be toxic! Glucuronidation (60%) Sulfation (35%) UGT GST CYP2E1(5%) Toxic!

  15. Ethnic Diversity Studies are Essential for Drug Development • Polymorphic allele distribution differs between ethnic groups – - therefore Drug Safety and Efficacy also differs. • A KEY PROBLEM:Most clinical trials are performed in Caucasians • Asians and Africans do not always enjoy thesame level of safety and efficacy from new medicines

  16. Heart failure in Caucasians vs. African-Americans Exner et al. (2001) NEJM344, 1351-1357 *Enalapril (ACE inhibitor)  No advantage for African-Americans

  17. CYP2D6 & CYP2C19 Luo et al (2004) American Journal of Pharmacogenomics 4: 395-401

  18. Middle Eastern Origin of the Jews Hammer et al. (2000) Proc Natl Acad Sci U S A 97, 6769-6774

  19. NLGIP Informed Consent Form • The blood sample shall be used for preparing a cell line for research and is not related to my medical care. • The repository must maintain the confidentiality of the information resulting from the research, and use it without any identifying details.

  20. Informed Consent Form(cont.)- Altruism is empahsized • My refusal to participate in this research will not affect my medical treatment in any way. • The individual information from such studies shall not be made available to me. • I shall not receive any benefit in return for giving my blood sample and this consent.

  21. Refusal do donate to NLGIP:Women and >50 are more likely to donate By Gender By Age Women 28% Men 43% Total 34% 18-30 37% 31-40 41% 41-50 39% 51-60 20% Over 60 25%

  22. Reasons for refusal do donate(asked to choose from 5 optional replies) 60%  Not willing to donate too much blood 24%  Worried that their identity will be exposed 8%  Do not want their genes to be studied 4%  Find it immoral to perform genetic studies 4%  Other reasons

  23. Personalized Medicine:Can it co-exist with healthcare equity? • What should we do about people who do not have the ‘right genotype’ for available medicines? • How can society ensure better equity in healthcare, along with better, more personalized, medicine? *** Questions? gurwitz@post.tau.ac.il

More Related